Qualitopix: An AI-Driven Solution for Standardizing Tissue Staining in Pathology - Visiopharm

Resources / Qualitopix: An AI-Driven Solution for Standardizing Tissue Staining in Pathology

Qualitopix®

Duration 44:12 min

Martin Kristensson, Visiopharm

Qualitopix: An AI-Driven Solution for Standardizing Tissue Staining in Pathology

Details

Duration 44:12 min

Watch now Details

About the webinar

Tissue staining is a critical step in the diagnosis and prognosis of various diseases, especially cancer. However, tissue staining quality can vary significantly due to factors such as reagents, protocols, instruments, even operators. This can lead to inconsistent and inaccurate results, affecting patient care and clinical research.

In this seminar presented at PathVisions 2023, Martin will discuss challenges for managing stain quality of immunohistochemical (IHC) and H&E, potential root causes and a practical QA/QC solution. Qualitopix uses artificial intelligence (AI) to analyze standardized, validated test materials over time, complementing external quality assessment (EQA)-led proficiency testing. He will go through real-world examples and research conducted through the last 12-18 months.

Key Learnings

Importance of Staining Consistency: One of the main takeaways is the critical role that staining consistency plays in accurate diagnostics. Ensuring consistency is vital for reliable test results in immunohistochemistry.
Role of Technology and AI: The seminar highlighted how advancements in AI and the development of new tools can significantly aid in monitoring and improving staining quality, thereby enhancing the overall diagnostic process.
Need for Standardization and Quality Control: The talk emphasized the need for standardization in staining procedures and the use of quality control measures. This is essential to cope with the challenges posed by the complexity and variability of tests in pathology labs.

Speaker

Martin Kristensson
Senior Vice President, Global Clinical Sales

Martin Kristensson is responsible for our global clinical commercial activities and teams. Together with his team, he coordinated the development of Visiopharm’s clinical products, and the change management processes used to implement the tools in the daily clinical routine across Denmark. In close collaboration with colleagues and customers, he continues to investigate new applications of image analysis within pathology, pursuing new ways of offering standardized high-quality data and diagnosis.

He received his M.Sc. in Biomedical Engineering from the Technical University of Denmark in 2011, specializing in Signal and Model-based Diagnostics, combined with Image Diagnostics and Radiation Physics. In 2014, he became a certified Project Manager.

Qualitopix®